In Vitro and in Vivo Antiproliferative and Trypanocidal Activities of Ruthenium No Donors.
From: Departamento de Química e Física Molecular, Instituto de Química de São Carlos-Universidade de São Paulo (USP), São Carlos, SP, Brazil.
British journal of pharmacology
- Publish Date: Sep 2007
- ISSN: 0007-1188
- Volume: 152
- Issue: 1
- Pages: 112-21
- Medium: Print
- Language: English
- Citation (JAMA): Silva J J N, Osakabe A L, Pavanelli W R, et al. In Vitro and in Vivo Antiproliferative and Trypanocidal Activities of Ruthenium No Donors.. Br. J. Pharmacol. Sep 2007;152:112-21
Abstract
BACKGROUND AND PURPOSE: Many compounds liberating NO (NO donors) have been used as therapeutic agents. Here we test two ruthenium nitrosyls, which release NO when activated by biological reducing agents, for their effects in vitro and in vivo against Trypanosoma cruzi, the agent responsible for the American trypanosomiasis (Chagas’ disease). EXPERIMENTAL APPROACH: Ruthenium NO donors were incubated with a partially drug-resistant strain of T. cruzi and the anti-proliferative and trypanocidal activities evaluated. In a mouse model of acute Chagas’ disease, trypanocidal activity was evaluated by measuring parasitemia, survival rate of infected mice and elimination of amastigotes in myocardial tissue. KEY RESULTS: In vitro, the observed anti-proliferative and trypanocidal activities of trans-[Ru(NO)(NH(3))(4)isn](BF(4))(3) and trans-[Ru(NO)(NH(3))(4)imN](BF(4))(3) were due to NO liberated upon reduction of these nitrosyls. Ru(NO)isn had a lower IC(50 epi) (67 microM) than the NO donor, sodium nitroprusside (IC(50 epi)=244 microM) and Ru(NO)imN (IC(50 try)=52 microM) was more potent than gentian violet (IC(50 try)=536 microM), currently used in the treatment of blood. Both ruthenium nitrosyls eliminated, in vivo, extracellular as well as intracellular forms of T. cruzi in the bloodstream and myocardial tissue and allowed survival of up to 80% of infected mice at a dose (100 nmol kg(-1) day(-1)) much lower than the optimal dose for benznidazole (385 micromol kg(-1) day(-1)). CONCLUSIONS AND IMPLICATIONS: Our data strongly suggest that NO liberated is responsible for the anti-proliferative and trypanocidal activities of the ruthenium NO donors and that these compounds are promising leads for novel and effective anti-parasitic drugs.
Mesh Headings (Keywords): Animals, Chagas Disease, Disease Models, Animal, Dose-Response Relationship, Drug, Gentian Violet, Heart, Inhibitory Concentration 50, Mice, Myocardium, Nitric Oxide, Nitric Oxide Donors, Nitroprusside, Parasitemia, Parasitic Sensitivity Tests, Ruthenium Compounds, Trypanocidal Agents, Trypanosoma cruzi
Check for Full Text / PubMed Unique Identifier (PMID): 17603548
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.